Real insight from the people actually doing the work: operators, engineers, and leaders across 17 B2B industries.
FDA’s interchangeable Wezlana nod for Stelara’s uses lands as interchangeability reviews speed up, a shift that changes formulary timing, pharmacy substitution
CDP spending is rising, but operations teams are rewriting specs around warehouse-native, zero-copy activation and consent controls.
Robert Half data shows UK employers planning headcount growth, while the World Economic Forum warns skill disruption is accelerating. Ops leaders should treat t
Vantage’s $25B “Frontier” plan in Texas lands as PwC sizes AI data center spend at $31.6T through 2050 and Frontier buyers add $915M more carbon removal demand.
One-minute audio briefs on the stories moving B2B across all 17 industries. Press play to catch up on what your market is acting on, then read the full story.
Get started
Book a 15-minute demo and we will map your experts to the content your market is searching for.
Or call us. No forms required. We pick up. 214-945-2512
The best thinking on B2B industries and the future of how markets communicate, delivered every Tuesday.
Join 3,000+ B2B marketing leaders. Unsubscribe any time.
Free workspace
These stories come from MarketScale. Create a free workspace and turn your own team's expertise into published media that buyers and AI engines actually cite. No credit card, no demo required.
NPS +73 · 1,000+ creators · 38+ countries
What you get, free
Real insight from the people actually doing the work: operators, engineers, and leaders across 17 B2B industries.
FDA interchangeable biosimilar approvals are accelerating, compressing formulary and pharmacy substitution timelines.
CDP buyers are rewriting procurement specs to demand warehouse-native, zero-copy activation and consent controls.
UK employers plan hiring growth, but skill disruption is accelerating faster than headcount can solve.
Vantage's 1.4GW Texas AI data center campus makes grid contracts the critical project schedule dependency.
One-minute audio briefs on the stories moving B2B across all 17 industries. Press play to catch up on what your market is acting on, then read the full story.
Regulatory and vendor ecosystems are collapsing decision cycles by embedding approval and activation into operational workflows.
Wezlana's accelerated interchangeability clearance is reshaping formulary timing in pharma, while Adobe and Optimizely are similarly compressing marketing handoffs and activation cycles by centralizing dashboards and log-native data flows.
Read source ↗interchangeable
Wezlana biosimilar approval speeds formulary substitution
FDA’s interchangeable Wezlana nod for Stelara’s uses lands as interchangeability reviews speed up, a shift that changes formulary timing, pharmacy substitution
Read source ↗Read source ↗“operations teams are rewriting specs around warehouse-native, zero-copy activation and consent controls”
— CDP buyer requirement shift, 2026-09-08
Get started
Book a 15-minute demo and we will map your experts to the content your market is searching for.
Or call us. No forms required. We pick up. 214-945-2512
The best thinking on B2B industries and the future of how markets communicate, delivered every Tuesday.
Join 3,000+ B2B marketing leaders. Unsubscribe any time.
